How many stocks are there of argenx?
The current number of stocks of argenx is 57.17 M undefined.
argenx Stocks 2024
argenx Stocks
57.17 M
Ticker
ARGX.BR
ISIN
NL0010832176
WKN
A11602
In 2024, argenx had 57.17 M outstanding stocks, a 0% change from the 57.17 M stocks in the previous year.
The argenx Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 57.17 |
| 2028e | 57.17 |
| 2027e | 57.17 |
| 2026e | 57.17 |
| 2025e | 57.17 |
| 2024e | 57.17 |
| 2023 | 57.17 |
| 2022 | 54.38 |
| 2021 | 51.08 |
| 2020 | 45.41 |
| 2019 | 38.62 |
| 2018 | 33.42 |
| 2017 | 24.61 |
| 2016 | 18.82 |
| 2015 | 15.73 |
| 2014 | 7.55 |
| 2013 | 7.55 |
| 2012 | 7.55 |
| 2011 | 7.55 |
argenx shares outstanding NL0010832176 · A11602
The number of shares was argenx in 2023 — This indicates how many shares 57.169 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue argenx earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates argenx's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of argenx’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating argenx's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 7.55 M Aktien |
| 2012 | 7.55 M Aktien |
| 2013 | 7.55 M Aktien |
| 2014 | 7.55 M Aktien |
| 2015 | 15.73 M Aktien |
| 2016 | 18.82 M Aktien |
| 2017 | 24.61 M Aktien |
| 2018 | 33.42 M Aktien |
| 2019 | 38.62 M Aktien |
| 2020 | 45.41 M Aktien |
| 2021 | 51.08 M Aktien |
| 2022 | 54.38 M Aktien |
| 2023 | 57.17 M Aktien |
| 2024e | 57.17 M Aktien |
| 2025e | 57.17 M Aktien |
| 2026e | 57.17 M Aktien |
| 2027e | 57.17 M Aktien |
| 2028e | 57.17 M Aktien |
| 2029e | 57.17 M Aktien |
argenx Aktienanalyse
What does argenx do?
Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. The company was founded in 2008 and is headquartered in Gent, Belgium. Argenx utilizes an innovative technology platform, the Simple Antibody platform, to develop customized antibodies with high efficacy. Argenx operates in two main business areas: clinical development and licensing. The company aims to produce outstanding therapeutic agents from each of its platform technologies and drug candidates, which can be used as antibody therapies against serious autoimmune diseases or cancer. Argenx's main product is the drug Efgartigimod, a monoclonal antibody developed for the treatment of multiple autoimmune diseases, particularly generalized Myasthenia Gravis (GMG). The drug is currently in clinical development. In recent years, Argenx has made significant progress in the development of new drugs. For example, the company has announced the discovery of new antibodies for the treatment of Myasthenia Gravis, rheumatoid arthritis, and various types of cancer. Licensing these development pipelines opens up new opportunities for Argenx to create additional therapy options for patients with serious illnesses. Argenx has also established partnerships with leading pharmaceutical companies such as Shire and AbbVie to expand its technology platform and drug candidates into new areas of application. The company is currently working on the development of therapies for rare and serious diseases that have no satisfactory treatment options. With the advancement of its innovative technology platform and the expansion of its portfolio of drug candidates, Argenx is on a promising path to play a leading role in the industry. The company is building an extensive network of partnerships and collaborations to accelerate the further development of its technology platform and products, and to achieve further success in the search for new therapeutic applications and areas of application. Looking ahead, Argenx is poised to play a significant role in the biopharmaceutical industry, particularly in the development of personalized therapy options for the treatment of serious diseases where no satisfactory treatment options currently exist. Argenx is proud of its dedicated team of employees who strive every day to realize the company's vision - to help patients cope with serious illnesses through new and innovative therapies. Output: Argenx SE is a biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of serious diseases. argenx ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating argenx's Shares Outstanding
argenx's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in argenx’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding argenx’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in argenx’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about argenx stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of argenx are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of argenx evolved in recent years?
The number of shares of argenx has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. argenx as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of argenx?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does argenx pay?
Over the past 12 months, argenx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, argenx is expected to pay a dividend of 0 USD.
What is the dividend yield of argenx?
The current dividend yield of argenx is .
When does argenx pay dividends?
argenx pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of argenx?
argenx paid dividends every year for the past 0 years.
What is the dividend of argenx?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is argenx located?
argenx is assigned to the 'Health' sector.
Wann musste ich die Aktien von argenx kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of argenx from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did argenx pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of argenx in the year 2023?
In the year 2023, argenx distributed 0 USD as dividends.
In which currency does argenx pay out the dividend?
The dividends of argenx are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The argenx stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von argenx
Our stock analysis for argenx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of argenx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
